3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
238
Precursor Cell Lymphoblastic Leukemia-Lymphoma
46
Recurrence
35
Burkitt Lymphoma
23
Neoplasms
20
Neoplasms, Plasma Cell
17
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
15
Immunoglobulin Light-chain Amyloidosis
13
Leukemia
12
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma
10
Lymphoma, Large B-Cell, Diffuse
9
Lung Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Prostatic Neoplasms
8
Leukemia, Biphenotypic, Acute
8
Neoplasm Metastasis
7
Lymphoma, Non-Hodgkin
7
Breast Neoplasms
7
Lymphoma, B-Cell
6
Smoldering Multiple Myeloma
5
Nausea
5
Leukemia, Myeloid, Acute
5
Hodgkin Disease
5
Brain Neoplasms
5
Waldenstrom Macroglobulinemia
4
Neoplasm, Residual
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Mantle-Cell
4
Amyloidosis
4
Interventions
enzalutamide
4
Docetaxel
3
abiraterone
2
Prednisone
2
Abiraterone Acetate
2
relugolix
1
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
Dexamethasone
×
1 year
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled